CDK12 and prostate cancer: This has prompted a shift toward mechanistic markers that reflect the inherently low immunogenicity of prostate cancer, such as mismatch repair deficiency (dMMR), a microsatellite instability-high (MSI-H) phenotype, and CDK12 gene alterations [87].